Originally published as JCO Early Release 10.1200/JCO.2007.14.0590 on May 5 2008

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gomez, H. L. Articles by Sledge, G. W. Search for Related Content PubMed PubMed Citation Articles by Gomez, H. L. Articles by Sledge, G. W. Related Articles Related Editorial Related Correspondence Social Bookmarking                            What's this?

Efficacy and Safety of Lapatinib As First-Line Therapy for ErbB2-Amplified Locally Advanced or Metastatic Breast Cancer

Henry L. Gomez, Dinesh C. Doval, Miguel A. Chavez, Peter C.-S. Ang, Zeba Aziz, Shona Nag, Christina Ng, Sandra X. Franco, Louis W.C. Chow, Michael C. Arbushites, Michelle A. Casey, Mark S. Berger, Steven H. Stein, George W. Sledge

From the Instituto Nacional de Enfermedades Neoplásicas; Oncology, Hospital Alberto Sabogal, Lima, Peru; Rajiv Gandhi Cancer Institute and Research Centre, New Delhi; Jehangir Hospital and Medical Centre, Pune, India; National Cancer Centre, Singapore; Allama Iqbal Medical College, Lahore, Pakistan; University Malaya Medical Centre, Kuala Lumpur, Malaysia; University of Hong Kong and Queen Mary Hospital, Pokfulam, Hong Kong; Memorial Cancer Institute, Hollywood, FL; Medicine Development Center Oncology, GlaxoSmithKline, Collegeville, PA; and Indiana University School of Medicine, Indianapolis, IN

Corresponding author: Henry L. Gomez, MD, Instituto Nacional de Enfermedades, Neoplásicas, Avenida Angamos, Este 2520, Lima 34, Peru; e-mail: hgomez{at}inen.sld.pe

Purpose This study (EGF20009) assessed the efficacy and tolerability of two lapatinib administration schedules as first-line monotherapy in women with ErbB2-amplified locally advanced or metastatic breast cancer.

Patients and Methods Patients with ErbB2-amplified, locally advanced or metastatic breast cancer previously untreated in the metastatic setting were randomly assigned to one of two lapatinib dose cohorts and received either 1,500 mg once daily or 500 mg twice daily. Clinical response was assessed at weeks 8 and 12 and every 12 weeks thereafter.

Results A total of 138 patients were treated with lapatinib for a median of 17.6 weeks. The overall response rate (complete response [CR] plus partial response [PR]) was 24% in the intent-to-treat population, and 31% of patients derived clinical benefit (CR, PR, or stable disease for 24 weeks). The median time to response was 7.9 weeks, and the progression-free survival rates at 4 and 6 months were 63% and 43%, respectively. The most common lapatinib-related adverse events (AEs) were diarrhea, rash, pruritus, and nausea, and these events were primarily grade 1 or 2. There were no significant differences in clinical activity or the AE profile between the dosing schedules.

Conclusion Lapatinib demonstrated clinical activity and was well tolerated as first-line therapy in ErbB2-amplified locally advanced or metastatic breast cancer. This study supports further evaluation of lapatinib in first-line and early-stage ErbB2-overexpressing breast cancer.

published online ahead of print at www.jco.org on May 5, 2008.

Supported by GlaxoSmithKline R&D Limited.

Presented in part in posters at the 41st Annual Meeting of the American Society of Clinical Oncology, May 13-17, 2005, Orlando, FL; 12th European Congress of Clinical Oncology, October 29-November 1, 2005, Paris, France; 28th Annual San Antonio Breast Cancer Symposium, December 8-11, 2005, San Antonio, TX; 29th Annual San Antonio Breast Cancer Symposium, December 14-17, 2006, San Antonio, TX; and 43rd Annual Meeting of the American Society of Clinical Oncology, June 1-5, 2007, Chicago, IL.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

Clinical Trials repository link available on www.JCO.org.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

Related Editorial

• Mathematics in the Realm of Lapatinib: 500 + 500 = 1,500?
  Bostjan Seruga and Ian F. Tannock
  JCO 2008 26: 2940-2942 [Full Text]

Related Correspondence

• How Should We Prescribe Lapatinib to Our Patients: Once Daily or Twice Daily, and at What Dose?
  Mariangela Ciccarese and Vito Lorusso
  JCO 2009 27: 314-315 [Full Text]

This article has been cited by other articles:

				S. Johnston, J. Pippen Jr, X. Pivot, M. Lichinitser, S. Sadeghi, V. Dieras, H. L. Gomez, G. Romieu, A. Manikhas, M. J. Kennedy, et al. Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor-Positive Metastatic Breast Cancer J. Clin. Oncol., November 20, 2009; 27(33): 5538 - 5546. [Abstract] [Full Text] [PDF]

				U. McDermott and J. Settleman Personalized Cancer Therapy With Selective Kinase Inhibitors: An Emerging Paradigm in Medical Oncology J. Clin. Oncol., November 20, 2009; 27(33): 5650 - 5659. [Abstract] [Full Text] [PDF]

				G. Capri, J. Chang, S.-C. Chen, P. Conte, K. Cwiertka, G. Jerusalem, Z. Jiang, S. Johnston, B. Kaufman, J. Link, et al. An open-label expanded access study of lapatinib and capecitabine in patients with HER2-overexpressing locally advanced or metastatic breast cancer Ann. Onc., November 2, 2009; (2009) mdp373v2. [Abstract] [Full Text] [PDF]

				S. Beslija, J. Bonneterre, H. J. Burstein, V. Cocquyt, M. Gnant, V. Heinemann, J. Jassem, W. J. Kostler, M. Krainer, S. Menard, et al. Third consensus on medical treatment of metastatic breast cancer Ann. Onc., November 1, 2009; 20(11): 1771 - 1785. [Abstract] [Full Text] [PDF]

				H. A. Burris III, C. W. Taylor, S. F. Jones, K. M. Koch, M. J. Versola, N. Arya, R. A. Fleming, D. A. Smith, L. Pandite, N. Spector, et al. A Phase I and Pharmacokinetic Study of Oral Lapatinib Administered Once or Twice Daily in Patients with Solid Malignancies Clin. Cancer Res., November 1, 2009; 15(21): 6702 - 6708. [Abstract] [Full Text] [PDF]

				T. Bekaii-Saab, J. Markowitz, N. Prescott, W. Sadee, N. Heerema, L. Wei, Z. Dai, A. Papp, A. Campbell, K. Culler, et al. A Multi-Institutional Phase II Study of the Efficacy and Tolerability of Lapatinib in Patients with Advanced Hepatocellular Carcinomas Clin. Cancer Res., September 15, 2009; 15(18): 5895 - 5901. [Abstract] [Full Text] [PDF]

				A. J. Chien, J. A. Illi, A. H. Ko, W. M. Korn, L. Fong, L.-m. Chen, M. Kashani-Sabet, C. J. Ryan, J. E. Rosenberg, S. Dubey, et al. A Phase I Study of a 2-Day Lapatinib Chemosensitization Pulse Preceding Nanoparticle Albumin-Bound Paclitaxel for Advanced Solid Malignancies Clin. Cancer Res., September 1, 2009; 15(17): 5569 - 5575. [Abstract] [Full Text] [PDF]

				R. S. Finn, M. F. Press, J. Dering, M. Arbushites, M. Koehler, C. Oliva, L. S. Williams, and A. Di Leo Estrogen Receptor, Progesterone Receptor, Human Epidermal Growth Factor Receptor 2 (HER2), and Epidermal Growth Factor Receptor Expression and Benefit From Lapatinib in a Randomized Trial of Paclitaxel With Lapatinib or Placebo As First-Line Treatment in HER2-Negative or Unknown Metastatic Breast Cancer J. Clin. Oncol., August 20, 2009; 27(24): 3908 - 3915. [Abstract] [Full Text] [PDF]

				K. L. Blackwell, M. D. Pegram, E. Tan-Chiu, L. S. Schwartzberg, M. C. Arbushites, J. D. Maltzman, J. K. Forster, S. D. Rubin, S. H. Stein, and H. J. Burstein Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens Ann. Onc., June 1, 2009; 20(6): 1026 - 1031. [Abstract] [Full Text] [PDF]

				J. S. Ross, E. A. Slodkowska, W. F. Symmans, L. Pusztai, P. M. Ravdin, and G. N. Hortobagyi The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti-HER-2 Therapy and Personalized Medicine Oncologist, April 1, 2009; 14(4): 320 - 368. [Abstract] [Full Text] [PDF]

				N. U. Lin, V. Dieras, D. Paul, D. Lossignol, C. Christodoulou, H.-J. Stemmler, H. Roche, M. C. Liu, R. Greil, E. Ciruelos, et al. Multicenter Phase II Study of Lapatinib in Patients with Brain Metastases from HER2-Positive Breast Cancer Clin. Cancer Res., February 15, 2009; 15(4): 1452 - 1459. [Abstract] [Full Text] [PDF]

				M. Ciccarese and V. Lorusso How Should We Prescribe Lapatinib to Our Patients: Once Daily or Twice Daily, and at What Dose? J. Clin. Oncol., January 10, 2009; 27(2): 314 - 315. [Full Text] [PDF]

				C. A. Castaneda and H. L. Gomez In Reply J. Clin. Oncol., January 10, 2009; 27(2): 315 - 316. [Full Text] [PDF]

				M. N. Dickler, H. S. Rugo, C. A. Eberle, E. Brogi, J. F. Caravelli, K. S. Panageas, J. Boyd, B. Yeh, D. E. Lake, C. T. Dang, et al. A Phase II Trial of Erlotinib in Combination with Bevacizumab in Patients with Metastatic Breast Cancer Clin. Cancer Res., December 1, 2008; 14(23): 7878 - 7883. [Abstract] [Full Text] [PDF]

				P. Paoletti Drug Development in the Targeted Therapy Era J. Clin. Oncol., August 1, 2008; 26(22): 3815 - 3816. [Full Text] [PDF]

				B. Seruga and I. F. Tannock Mathematics in the Realm of Lapatinib: 500 + 500 = 1,500? J. Clin. Oncol., June 20, 2008; 26(18): 2940 - 2942. [Full Text] [PDF]